Revuforj (revumenib) is an oral, first-in-class menin inhibitor that is FDA approved for the treatment of relapsed or refractory (R/R) acute leukemia with a lysine methyltransferase 2A gene (KMT2A) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback